 |
|---|
| As Of | Filer | Doc Filing¹ | For·On·As | Docs:Size | Issuer | | Filing Agent | |
|---|
|
|---|
6/3/22 Healthcare Solutions Mgmt Gp, Inc 10-K 9/30/21 45:2.6M Discount Edgar/FA
1: 10-K Annual Report -- HTML: 666K| 10-K | 1st Page of 115± | Healthcare Solutions Mgmt Gp, Inc - 10-K | No Page-Breaks | | Line 226: Receiver and certain entities, as directed by the Receiver, were issued an aggregate total of 114,599,754 pre-reverse ... subsidiary and the business of HSH became the business of the Company going forward. Accordingly, at the Closing,
the Company ceased to be a shell company as of April 15, 2021 . In connection with the Merger, the Company ... Chief Financial Officer and as the Executive Chairman and member of the Board of Directors of the Company . On
April 15, 2021 , Dr. Charles Balaban was appointed as a member of the Board of Directors of the Company . On April 15, 2021 , Jonathan Loutzenhiser ... Vice President of the Company and a member of the Board of Directors of the Company . On April 15, 2021 , Dr.
Joseph Asuncion was appointed as a member of the Board of Directors of the Company and as the Company ’s Chief Medical Officer. On April 15, 2021 , Dr. Sadeem Mahmood was appointed as the Company ’s Chief of Surgery. On April 15, 2021 , Dr. Richard F. Wittock was appointed as the Company ’s Vice President of Clinical Affairs. On April 15, 2021 , Dr. Richard Muckerman was appointed ... | | Line 472: ... of Contents Part III Item 10. Directors, Executive Officers and Corporate Governance. DIRECTORS AND EXECUTIVE ... table sets forth the name and position of our current executive officers and directors. Name Age Position Justin
Smith 41 Interim Chief Executive Officer, Interim Chief Financial Officer, Executive Chairman and Director Jonathan Loutzenhiser 35 Executive Vice President and Director Dr. Joseph Asuncion 59 Chief Medical Officer and Director Dr.
Charles Balaban 72 Director Dr. Sadeem Mahmood 58 Chief of Surgery Dr. Richard Muckerman 70 Vice President of Strategy and Business Blake Moorman 40 Vice President of Operations Dr.
Richard F. Wittock 49 Vice President of Clinical Affairs Justin Smith . On April 15, 2021 , Justin Smith was ... and as the Executive Chairman and member of the Board of Directors of the Company . Justin Smith is a professional ... | | Line 479: ... of HSH since he was appointed to such positions on October 1, 2017 and holds this position to date. Mr. Loutzenhiser graduated from Grace University with a degree in business management in 2012. Dr. Joseph Asuncion . On April 15, 2021 , Dr. Joseph Asuncion was appointed as a member of the Board of Directors of the Company and as the Company ’s Chief Medical Officer. Dr. Asuncion has been serving and remains a Director of HSH since he was appointed to that position on November
7, 2019 . Dr. Asuncion attended the University of Maryland where he received his BS in Biology, then received his Doctorate of Medicine at the Perpetual Help College of Medicine in the Philippines. From 2015 to 2017, Dr. Asuncion served as a director on the Board of Directors of IneedMD. From 2010 to 2020 Dr. Asuncion was a director and staff physician at Meritus Family Practice. He has dedicated himself to the practice of ... include Diplomate of the American Academy of Family Medicine and Basic/Advanced Cardiac Life Support Provider. Dr.
Charles Balaban . On April 15, 2021 , Dr. Charles Balaban was appointed as a member of the Board of Directors of the Company . Dr. Balaban was appointed as a Director of HSH on October 1, 2017 and serves in this capacity to date. Dr. Balaban received his D.D.S. in dentistry from the University of Toronto in 1973. Since 2015, Dr. Balaban has worked as the owner and operator of a multi-practitioner dental/surgical clinic. Dr. Balaban has been the principal of numerus rollup and M&A transaction in the dental/surgical industry dating back 25 years. He is also a serial entrepreneur and active investor in the medical device industry. Dr. Sadeem Mahmood.
On April 15, 2021 , Dr. Sadeem Mahmood was appointed as the Company ’s Chief of Surgery. Interventional Cardiologist Sadeem Mahmood, M.D. ... is board-certified in Internal Medicine, Cardiovascular Medicine, Interventional Cardiology, and Nuclear Cardiology. Dr. Mahmood previously sat on the Board of Cardiovascular Group for St. Vincent’s Hospital for a total of seven years; ... College of Cardiology and is a member of the American Society of Medicine and the Arkansas Society of Medicine. Dr. Mahmood ... | | Line 494: Other Compensation ($) Total ($) Justin Smith (1) 2021 $ - $ - $ - $ - Executive
Chairman, principal executive officer, and principal financial and accounting officer 2020 $ - $ - $ - $ - Dr
Charles Balaban (2) 2021 $ - $ - $ - $ - Director 2020 $ - $ - $ - $ - Jonathan
Loutzenhiser (3) 2021 $ 225,000.00 $ - $ - $ 225,000.00 Executive Vice President and Director 2020 $ 225,000.00 $ - $ - $ 225,000.00 Dr. | | Line 503: Stevens (9) 2021 $ - $ - $ - $ - Former Receiver 2020 $ - $ - $ 3,555 (1) $ 3,555 _________________ (1) On
April 15, 2021 , Justin Smith was appointed as the Company ’s Interim Chief Executive Officer, Interim Chief ... the Executive Chairman and member of the Board of Directors of the Company . 47 Table of Contents (2) On April
15, 2021 , Dr. Charles Balaban was appointed as a member of the Board of Directors of the Company . (3) On April 15, 2021 , Jonathan Loutzenhiser was appointed as Executive Vice President of the Company and a member of the Board of Directors of the Company .
(4) On April 15, 2021 , Dr. Joseph Asuncion was appointed as a member of the Board of Directors of the Company and as the Company ’s Chief Medical Officer. (5) On April 15, 2021 , Dr. Sadeem Mahmood was appointed as the Company ’s Chief of Surgery. (6) On April ... | | Line 518: ... for a particular person, all shares of our common stock outstanding on that date and all shares of our common stock ... to the extent that power may be shared with a spouse. 49 Table of Contents Name of Beneficial Owner: Amount
and Nature of Beneficial Ownership (2) Percent of Class (1) Directors and Executive Officers Justin Smith (3) 996,520 1.08 Dr.
Charles Balaban (4) 22,539,450 24.48 Jonathan Loutzenhiser (5) 22,000,000 23.89 Dr.
Joseph Asuncion (6) 539,450 * Dr. Sadeem Mahmood (7) 0 * Dr. Richard F. Wittock (8) 96,652 * Dr. | | Line 523: ... than 5% Holders Jackson Hole Medical Advisors, Inc. (11) 22,000,000 23.89 168 Capital Inc. (12) 9,249,130 10.05 _____________________ (1) Beneficial
ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with ... Company ’s common stock issued and outstanding as of the date of this Annual Report. (3) On April 15, 2021 , Justin
Smith was appointed as the Company ’s Interim Chief Executive Officer, Interim Chief Financial Officer and as the ... 996,520 shares of the Company ’s common stock held by Landes And Compagnie Trust Prive KB. (4) On April 15, 2021 , Dr. Charles Balaban was appointed as a member of the Board
of Directors of the Company . Dr. Balaban has voting and dispositive control of 22,514,537 shares of the Company ’s common stock held by Black Label Services, ... appointed as Executive Vice President of the Company and a member of the Board of Directors of the Company . (6) On
April 15, 2021 , Dr. Joseph Asuncion was appointed as a member of the Board of Directors of the Company and as the Company ’s Chief Medical Officer. Dr. Asuncion has voting and dispositive control of 514,537 shares of the Company ’s common stock held by Medical Tech Group Inc. (7) On April 15, 2021 , Dr. Sadeem Mahmood was appointed as the Company ’s ... | | Line 532: ... as applicable, in connection with the transactions described below were comparable to terms available or the amounts ... party. During the year ended June 30, 2019 , the Receiver incurred $8,838 in professional fees in managing the
Company . Additionally, the Receiver extended a loan of $65,000 to the Company , which bore interest at 10% and which ... August 25, 2020 . The Receiver Shares were issued on August 27, 2020 , and consisted of a total of 114,599,754 shares
of Company common stock, 38,199,918 of which were issued to Thistle Investments LLC. Jodi Stevens is the Manager of ... that have extended interest free demand loans. These related parties are as follows: (1) BLS, Inc. is controlled by Charles Balaban, a Director of the Company (2) BOAM,
Inc. is controlled by Charles Balaban (3) Healthcare Solutions DX, Inc. is controlled by Justin Smith , Chairman of the Company ’s Board of Directors ... Inc. is controlled by Doug Millar, head of the Company ’s Corporate Compliance and Regulatory Matters (5) Jonathan
Loutzenhiser – is a Vice President of the Company . Balance Due Balance Due 9/30/2021 9/30/2020 BLS, ... | | Line 685: ... and $ i 83,087,469 respectively. These investment are comprised of securities that trade frequently with quoted prices. ... to meet regulatory requirements for certain healthcare companies. For the fiscal year ended September 30, 2021 the
Company recorded an unrealized gains on investments of $ i 5,598,328 compared to a unrealized loss on investments of $ i 1,137,548 for the fiscal year ended September 30, 2020 , respectively. / i NOTE
5 – RELATED PARTY TRANSACTIONS Since the inception of the Company , substantially all of the funding for Company has ... that have extended interest free demand loans. These related parties are as follows: (1) BLS, Inc. is controlled by Charles Balaban, a Director of the Company (2) BOAM, Inc. is controlled by Charles Balaban (3) Healthcare
Solutions DX, Inc. is controlled by Justin Smith , Chairman of the Company ’s Board of Directors (4) JHMA, Inc. ... the Company ’s Corporate Compliance and Regulatory Matters (5) Jonathan Loutzenhiser – is a Vice President of the ... | | Line 744: Justin Smith Interim Chief Executive Officer and Interim Chief Financial Officer and Director June 3, 2022 Justin ... officer and principal financials and accounting officer) /s/ Jonathan Loutzenhiser Director June
3, 2022 Jonathan Loutzenhiser /s/ Dr. Joseph Asuncion Director June 3, 2022 Dr. Joseph Asuncion /s/
Dr. Charles Balaban Director June 3, 2022 Dr. Charles Balaban 56
|
2: EX-31.1 Certification -- §302 - SOA’02 -- HTML: 21K
3: EX-32.1 Certification -- §906 - SOA’02 -- HTML: 17K
9: R1 Cover -- HTML: 78K
10: R2 Consolidated Balance Sheets -- HTML: 118K
11: R3 Consolidated Balance Sheets (Parenthetical) -- HTML: 24K
12: R4 Consolidated Statements of Operations -- HTML: 86K
13: R5 Consolidated Statements of Changes in Stockholders’ Equity --
HTML: 62K
14: R6 Consolidated Statements of Cash Flows -- HTML: 82K
15: R7 Organization and Business Background -- HTML: 28K
16: R8 Summary of Significant Accounting Policies -- HTML: 54K
17: R9 Accounts Receivable -- HTML: 21K
18: R10 Investments -- HTML: 18K
19: R11 Related Party Transactions -- HTML: 30K
20: R12 Debt -- HTML: 27K
21: R13 Shareholders Equity -- HTML: 25K
22: R14 Commitments and Contingencies -- HTML: 19K
23: R15 Income Taxes -- HTML: 21K
24: R16 Subsequent Events -- HTML: 28K
25: R17 Summary of Significant Accounting Policies (Policies) -- HTML: 97K
26: R18 Summary of Significant Accounting Policies (Tables) -- HTML: 18K
27: R19 Accounts Receivable (Tables) -- HTML: 20K
28: R20 Related Party Transactions (Tables) -- HTML: 24K
29: R21 Debt (Tables) -- HTML: 20K
30: R22 Organization and Business Background (Details Narrative) --
HTML: 19K
31: R23 Summary of Significant Accounting Policies (Details) -- HTML: 27K
32: R24 Summary of Significant Accounting Policies (Details Narrative) --
HTML: 20K
33: R25 Accounts Receivable (Details) -- HTML: 20K
34: R26 Investments (Details Narrative) -- HTML: 19K
35: R27 Related Party Transactions (Details) -- HTML: 27K
36: R28 Debt (Details) -- HTML: 22K
37: R29 Shareholders Equity (Details Narrative) -- HTML: 23K
38: R30 Commitments and Contingencies (Details Narrative) -- HTML: 16K
39: R31 Income Taxes (Details Narrative) -- HTML: 15K
40: R32 Subsequent Events (Details Narrative) -- HTML: 42K
43: XML IDEA XML File -- Filing Summary -- XML: 74K
41: XML XBRL Instance -- hsmg_10k_htm -- XML: 337K
42: EXCEL IDEA Workbook of Financial Report Info -- XLSX: 48K
6: EX-101.CAL XBRL Calculations -- hsmg-20210930_cal -- XML: 93K
8: EX-101.DEF XBRL Definitions -- hsmg-20210930_def -- XML: 125K
5: EX-101.LAB XBRL Labels -- hsmg-20210930_lab -- XML: 402K
7: EX-101.PRE XBRL Presentations -- hsmg-20210930_pre -- XML: 300K
4: EX-101.SCH XBRL Schema -- hsmg-20210930 -- XSD: 83K
44: JSON XBRL Instance as JSON Data -- MetaLinks -- 173± pages: 217K
45: ZIP XBRL Zipped Folder -- 0001477932-22-004099-xbrl -- Zip: 133K
| ____________ | | ¹ | Filing/Form and Document/Exhibit Types: -Q | | 10-K | Annual Report — Form 10-K. | | EX-31 | Certification — §302 – SOA’02. | | EX-32 | Certification — §906 – SOA’02. | | XML & R# | IDEA Financial Report Info. | | EXCEL | IDEA Workbook of Financial Report Info. | | EX-101 | XBRL Data. | | JSON | XBRL Instance as JavaScript Object Notation Data. | | ZIP | XBRL Zipped Folder. |
|
